HOME >> MEDICINE >> NEWS
New nationwide study in six cities will look at the method & message for changing risky HIV behavior

A nationwide study being launched in six U.S. cities is designed to answer one of the major unknowns of the AIDS epidemic: What type of one-on-one counseling is most effective in changing high-risk behavior to prevent HIV infection?

The study is one of the first large-scale research projects to focus on this question. Conducted by the HIV Network for Prevention Trials and funded by the National Institute of Allergy and Infectious Diseases, it is being coordinated by a national team headed by AIDS researchers in San Francisco and New York.

"HIV prevention counseling programs have been widespread since 1985. A few studies have evaluated their impact, but none has directly compared different approaches. Our goal is to determine the most effective prevention counseling program, so in the future resources can be put to the best use," said Patrick Barresi, MPH, project coordinator and associate specialist in the Center for AIDS Prevention Studies (CAPS) at the University of California San Francisco.

Project co-chairs are Thomas Coates, PhD, executive director of the UCSF AIDS Research Institute and director of UCSF CAPS; Margaret Chesney, PhD, UCSF professor of medicine and co-director of UCSF CAPS; and Beryl Koblin, PhD, associate member, laboratory of epidemiology, New York Blood Center.

The study, named EXPLORE, will compare two behavior interventions: standard HIV risk reduction counseling based on a research model called Project Respect that was developed by the Centers for Disease Control and Prevention, and a client-centered counseling approach developed by Coates, Chesney, and Barresi of UCSF.

Study volunteers currently are being recruited in Boston, Chicago, Denver, New York City, San Francisco, and Seattle through local health centers and departments. Participants must be men who have sex with men, are HIV-negative, are at least 16 years old, and have been sexually active within the past 12 months.

Researchers hope to enroll 72
'"/>

Contact: Corinna Kaarlela
ckaarlela@pubaff.ucsf.edu
415-476-3804
University of California - San Francisco
12-Jul-1999


Page: 1 2 3

Related medicine news :

1. Hopkins convenes consensus conference to develop blueprint for nationwide matching program
2. Rehabilitation professionals in nationwide survey cite barriers to assistive technology transfer
3. Churches nationwide issue plea for increased rates of African American organ donation
4. Sister study opens nationwide
5. Major prostate-cancer prevention study to launch awareness campaign in churches nationwide
6. Brain images from patients with schizophrenia will be shared in first nationwide imaging network
7. Lombardi Cancer Center to enroll current and former smokers in nationwide clinical trial
8. Rush conducts nationwide study to find genetic markers for depression
9. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
10. UMaine study looks at infants and chronic nighttime crying
11. Chronic pain treatments more effective when taken together, new study shows

Post Your Comments:
(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... relationships. With the help of Texas Counseling’s Sexuality ... of communication, and the development of healthier habits ... group workshops available for both couples and individuals ... couples enhance their relationships and learn skills to ...
(Date:5/21/2013)... Brazilian funding agency for scientific and technological research So ... So Paulo, announced an investment estimated in US$ 680 ... (RIDCs) for a period of up to eleven years, ... 7. , Funding for the 17 RIDCs will ... faculty, technicians, support personnel, and infrastructure). Host institutions will ...
(Date:5/21/2013)... Go Classy Tours, the oldest and ... redesigned their website featuring N Resort in Jamaica ... bars and dining. The website, which has always featured ... guest reviews, will now have a broader range of ... on culinary local recipes, flora and fauna, featured pictures ...
(Date:5/21/2013)... va (PRWEB) May 21, 2013 ... critical technology and management consulting solutions to the ... of Business Development. In the newly created ... leading all aspects of the firm’s business development ... and proposal management functions, and leading strategies to ...
Breaking Medicine News(10 mins):Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Research at the cutting edge of knowledge 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2
(Date:5/21/2013)... NEW YORK , May 21, 2013 ... market research report is available in its ... Global Markets and Technologies for Optical Coherence ...   STUDY OBJECTIVES ... conducting this study is to offer synopsis ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... U.S. spending on specialty prescription drugs — ... cancer, multiple sclerosis and rheumatoid arthritis — is projected ... according to a forecast released today by Express Scripts ... "As we see what,s on the ... act so they can continue to offer an affordable ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
Cached News: